MedPath

Proteomics of Severe Traumatic Brain Injury: A Feasibility Study

Conditions
Brain Injuries, Traumatic
Registration Number
NCT00522496
Lead Sponsor
University of Calgary
Brief Summary

The purpose of this study is to:

1. Determine the temporal course of matrix metalloproteinase (MMP) expression in patients wiht severe traumatic brain injury

2. Determine the temporal course of the expression of MMP-related inflammatory mediators of secondary injury in patients with severe traumatic brain injury

3. Describe the association of physiological changes and standard microdialysis analyte measures (lactate, pyruvate, lactate/pyruvate ratio, and glucose) to MMP and neuroinflammatory marker concentrations.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
8
Inclusion Criteria
  • Patient is 18 years of age or older
  • Patient has GCS less than 9
  • Patient requires intracranial pressure monitoring
  • Patient life expectancy greater than 72 hours
Exclusion Criteria
  • Patient's TBI is greater than 24 hours old
  • Patient is less than 18 years of age
  • Patient does not require intracranial pressure monitoring
  • Patient has life expectancy less than 72 hours
  • Patient has GCS greater or equal to 9
  • Patient is currently enrolled in another study

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Foothills Medical Centre

🇨🇦

Calgary, Alberta, Canada

Foothills Medical Centre
🇨🇦Calgary, Alberta, Canada
David A Zygun, MD
Principal Investigator
John Hurlbert, MD
Sub Investigator
Ian Parney, MD
Sub Investigator
Walter Hader, MD
Sub Investigator
Clare Gallagher, MD
Sub Investigator
Wee Yong, P.hD
Sub Investigator
Christopher Doig, MD
Sub Investigator
Paul Kubes, MD
Sub Investigator
Andreas Kramer, MD
Sub Investigator
© Copyright 2025. All Rights Reserved by MedPath